Drug Trial Radar · NCT05348785
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
650
Actual
Start
Apr 19, 2022
Primary completion
Mar 9, 2026
Study completion Mar 9, 2026
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- Denali Therapeutics Inc.
- First posted
- Apr 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about BIIB122 in participants with early-stage Parkinson's disease (PD). The study will include adults aged 30 to 80 who were diagnosed with PD within 2 years of starting the study. The main objective of the study is to learn about the effect BIIB122 has on slowing down the worsening of PD symptoms. The main question researchers want to answer is: \- How long does it take for PD symptoms to worsen during BIIB122 treatment? Researchers will answer this and other questions by measuring the symptoms of PD over time using a variety of scoring tools. These include the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the modified Schwab and England Activities of Daily Living Scale (mSE-ADL). The MDS-UPDRS is used to measure symptoms of PD. It has 4 parts: Part I, II, III, and IV. Each part measures different aspects of motor and non-motor symptoms. The mSE-ADL measures a participant's ability to perform daily activities or personal chores. Researchers will also learn more about the safety of BIIB122. They will check participants for adverse events. Adverse events are unwanted health problems that may or may not be caused by the study drug. The study will be done as follows: * Participants will be randomly assigned to take either BIIBB122 or placebo. A placebo looks like the study drug but contains no real medicine. * Neither the researchers nor the participants will know if the participants are receiving BIIB122 or placebo. * Participants will take BIIB122 or placebo tablets by mouth once a day. * The treatment period for each participant will last between 48 and 144 weeks. * There will be a safety follow-up period for 2 weeks after the last dose of BIIB122. * In total, participants will have up to 29 study visits. * Participants will stay in the study for at least 1 year, up to about 3 years.
Conditions
- Parkinson Disease
Interventions
BIIB122Drug
Administered as specified in the treatment arm
BIIB122-Matching PlaceboDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score Over the Treatment PeriodTime frame: Up to Week 144
Locations
113 sites in 13 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
University of Southern California
Los Angeles, California
Cedars Sinai
Los Angeles, California
SC3 Research Group Inc.
Pasadena, California
University of California San Francisco (UCSF)
San Francisco, California
University of Colorado
Aurora, Colorado
CenExel Rocky Mountain Clinical Research
Englewood, Colorado
Invicro
New Haven, Connecticut
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
University of Miami
Miami, Florida
Adventist Health System/Sunbelt, Inc.
Orlando, Florida
USF Health Byrd Institute
Tampa, Florida
Hawaii Pacific Neuroscience, LLC
Honolulu, Hawaii
Northwestern University
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas
Boston University Medical Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Quest Research Institute
Farmington Hills, Michigan
Mount Sinai Beth Israel
New York, New York
Weill Medical College of Cornell University
New York, New York
Duke Movement Disorders Clinic
Durham, North Carolina
The Cleveland Clinic Foundation
Cleveland, Ohio
UPHS
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Neurology Clinic, PC
Cordova, Tennessee
The Methodist Hospital Research Institute
Houston, Texas
Central Texas Neurology Consultants
Round Rock, Texas
Virginia Commonwealth University Department of Neurology
Richmond, Virginia
Evergreen Hospital Medical Center
Kirkland, Washington
Inland Northwest Research
Spokane, Washington
Klinik Ottakring
Vienna, Austria
Medizinische Universität
Innsbruck, Tyrol, Austria
University of Calgary
Calgary, Alberta, Canada
True North Clinical Research
Halifax, Nova Scotia, Canada
Toronto Western Hospital
Toronto, Ontario, Canada
CHUM Centre de Recherche
Montreal, Quebec, Canada
Montreal Neurological Institute
Montreal, Quebec, Canada
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.